Premium
Intravenous Bisphosphonate Therapy Increases Radial Width in Adults With Osteogenesis Imperfecta
Author(s) -
Gatti Davide,
Viapiana Ombretta,
Lippolis Irma,
Braga Vania,
Prizzi Rosangela,
Rossini Maurizio,
Adami Silvano
Publication year - 2005
Publication title -
journal of bone and mineral research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.882
H-Index - 241
eISSN - 1523-4681
pISSN - 0884-0431
DOI - 10.1359/jbmr.050312
Subject(s) - medicine , bisphosphonate , osteogenesis imperfecta , osteoporosis , urology , bone density , vitamin d and neurology , bone mineral , randomized controlled trial , endocrinology , anatomy
Neridronate therapy in adult patients with OI significantly increases the cross‐sectional area of the proximal radius. This observation may provide an additional explanation for the antifracture efficacy of bisphosphonates. Introduction: Bisphosphonate therapy decreases by 70‐90% the fracture risk in patients with osteogenesis imperfecta (OI). This decrease is somewhat greater than that expected from the BMD changes, supporting the hypothesis that bisphosphonate therapy is associated with structural changes, not detectable by BMD measurements. Materials and Methods: To explore this hypothesis, pQCT measurements at the nondominant radius were obtained in a group of adult OI patients participating in a randomized clinical trial with neridronate. Results: The total volumetric BMD of the ultradistal radius rose significantly in patients treated with neridronate and calcium + vitamin D (neridronate group) compared with patients treated with calcium + vitamin D alone (control group). No significant differences were observed in trabecular BMD and in volumetric cortical density in either group. In the neridronate group, the cross‐sectional area rose significantly versus both baseline values and the control group. These latter changes were associated with ∼20% increases in bending breaking resistance index (BBRI). Conclusion: Our observation, if extended to postmenopausal osteoporosis, may provide a new explanation for the fracture risk reduction observed in osteoporotic patients treated with bisphosphonates.